UBS Investment Bank is helping manage Windward Bio Group AG's IPO, but the report gives no fee or expected income for UBS. The sale still depends on closing conditions, so this does not change what we know about UBS's outlook.
This role may bring UBS fees, but the announcement gives no fee amount or expected income. The sale also depends on closing conditions, so its contribution to UBS cannot be judged from this report.
Follow UBS Investment Bank (UBS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for UBS